Satsuma Pharmaceuticals, Inc. Research and Development Expense
Satsuma Pharmaceuticals, Inc. reported Research and Development Expense of $7.46 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-05-11
- Satsuma Pharmaceuticals, Inc. research and development expense for the quarter ending 2023-03-31 was $7.46M, a 35.45% decline year-over-year.
- Satsuma Pharmaceuticals, Inc. research and development expense for the quarter ending 2022-12-31 was $8.70M, a 26.70% decline year-over-year.
- Satsuma Pharmaceuticals, Inc. research and development expense for the quarter ending 2022-09-30 was $11.34M, a 11.52% increase year-over-year.
- Satsuma Pharmaceuticals, Inc. research and development expense for the quarter ending 2022-06-30 was $12.50M, a 48.00% increase year-over-year.
- Satsuma Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $44.09M, a 17.16% increase from fiscal 2021.
- Satsuma Pharmaceuticals, Inc. research and development expense for fiscal 2021 was $37.63M, a 3.76% increase from fiscal 2020.
- Satsuma Pharmaceuticals, Inc. research and development expense for fiscal 2020 was $36.27M, a 49.90% increase from fiscal 2019.
- Satsuma Pharmaceuticals, Inc. research and development expense for fiscal 2019 was $24.20M, a 276.12% increase from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $7.46M 10-Q · filed 2023-05-11 | $16.16M derived: sum of 2 quarters · filed 2023-05-11 | $27.50M derived: sum of 3 quarters · filed 2023-05-11 | $39.99M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $20.04M derived: sum of 2 quarters · filed 2023-03-28 | $32.54M derived: sum of 3 quarters · filed 2023-03-28 | $44.09M 10-K · filed 2023-03-28 |
| 2022-09-30 | $11.34M 10-Q · filed 2022-11-03 | $23.84M derived: sum of 2 quarters · filed 2022-11-03 | $35.39M 10-Q · filed 2022-11-03 | $47.26M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | $12.50M 10-Q · filed 2022-08-09 | $24.05M 10-Q · filed 2022-08-09 | $35.92M derived: sum of 3 quarters · filed 2023-05-11 | $46.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | $11.56M 10-Q · filed 2023-05-11 | $23.42M derived: sum of 2 quarters · filed 2023-05-11 | $33.59M derived: sum of 3 quarters · filed 2023-05-11 | $42.03M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $22.04M derived: sum of 2 quarters · filed 2023-03-28 | $30.48M derived: sum of 3 quarters · filed 2023-03-28 | $37.63M 10-K · filed 2023-03-28 |
| 2021-09-30 | $10.17M 10-Q · filed 2022-11-03 | $18.61M derived: sum of 2 quarters · filed 2022-11-03 | $25.77M 10-Q · filed 2022-11-03 | $34.81M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $8.44M 10-Q · filed 2022-08-09 | $15.60M 10-Q · filed 2022-08-09 | $24.64M derived: sum of 3 quarters · filed 2022-08-09 | $33.39M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $7.16M 10-Q · filed 2022-05-10 | $16.20M derived: sum of 2 quarters · filed 2022-05-10 | $24.95M derived: sum of 3 quarters · filed 2022-05-10 | $33.78M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $17.79M derived: sum of 2 quarters · filed 2022-03-15 | $26.62M derived: sum of 3 quarters · filed 2022-03-15 | $36.27M 10-K · filed 2022-03-15 |
| 2020-09-30 | $8.75M 10-Q · filed 2021-11-09 | $17.58M derived: sum of 2 quarters · filed 2021-11-09 | $27.23M 10-Q · filed 2021-11-09 | $36.38M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $8.83M 10-Q · filed 2021-08-10 | $18.48M 10-Q · filed 2021-08-10 | $27.63M derived: sum of 3 quarters · filed 2021-08-10 | $35.07M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $9.65M 10-Q · filed 2021-05-11 | $18.80M derived: sum of 2 quarters · filed 2021-05-11 | $26.24M derived: sum of 3 quarters · filed 2021-05-11 | $31.69M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $16.59M derived: sum of 2 quarters · filed 2021-03-25 | $22.05M derived: sum of 3 quarters · filed 2021-03-25 | $24.20M 10-K · filed 2021-03-25 |
| 2019-09-30 | $7.44M 10-Q · filed 2020-11-10 | $12.90M derived: sum of 2 quarters · filed 2020-11-10 | $15.05M 10-Q · filed 2020-11-10 | $17.00M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $5.46M 10-Q · filed 2020-08-11 | $7.61M 10-Q · filed 2020-08-11 | $9.56M derived: sum of 3 quarters · filed 2020-08-11 | $10.94M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $2.15M 10-Q · filed 2020-05-12 | $4.10M derived: sum of 2 quarters · filed 2020-05-12 | $5.48M derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $3.33M derived: sum of 2 quarters · filed 2020-03-10 | $6.43M 10-K · filed 2020-03-10 | |
| 2018-09-30 | $1.38M 10-Q · filed 2019-11-12 | $4.48M 10-Q · filed 2019-11-12 | ||
| 2017-12-31 | $4.19M 10-K · filed 2020-03-10 |